Loka Raghu Kumar Penke

Dr. Loka Raghu Kumar Penke


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 April 2015 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
EBEmilie Bourdonnay
Emilie Bourdonnay
ZZZbigniew Zasłona
Zbigniew Zasłona
LPLoka Raghu Kumar Penke
Loka Raghu Kumar Penke
JSJennifer Speth
Jennifer Speth
DSDaniel J. Schneider
Daniel J. Schneider
MPMarc Peters-Golden
Marc Peters-Golden
JAK-STAT signaling mediates the actions of numerous cytokines and growth factors, and its endogenous brake is the family of SOCS proteins. Consistent with their intracellular roles, SOCS proteins have never been identified in the extracellular space. Here we report that alveolar macrophages can secrete SOCS1 and -3 in exosomes and microparticles, respectively, for uptake by alveolar epithelial cells and subsequent inhibition of STAT activation. Secretion is tunable and occurs both in vitro and in vivo. SOCS secretion into lung lining fluid was diminished by cigarette smoking in humans and mice. Secretion and transcellular delivery of vesicular SOCS proteins thus represent a new model for the control of inflammatory signaling, which is subject to dysregulation during states of inflammation.

1 May 2013 in American Journal of Respiratory Cell and Molecular Biology
Verified
Journal Article
Closed access
GGGarth Garrison
Garth Garrison
SHSteven K. Huang
Steven K. Huang
KOKatsuhide Okunishi
Katsuhide Okunishi
JSJacob P. Scott
Jacob P. Scott
LPLoka Raghu Kumar Penke
Loka Raghu Kumar Penke
MPMarc Peters-Golden
Marc Peters-Golden
Differentiation of fibroblasts into α-smooth muscle actin (SMA)–expressing myofibroblasts represents a critical step in the pathogenesis of fibrotic disorders, and is generally regarded as irreversible. Prostaglandin E2 (PGE2) has been shown to prevent multiple aspects of fibroblast activation, including the differentiation of fibroblasts to myofibroblasts. Here, we investigated its ability to reverse this differentiated phenotype. Fetal and adult lung fibroblasts were induced to differentiate into myofibroblasts by 24-hour culture with transforming growth factor (TGF)-β1 or endothelin-1. Cells were then treated without or with PGE2 for various intervals and assessed for α-SMA expression. In the absence of PGE2 treatment, α-SMA expression induced by TGF-β1 was persistent and stable for up to 8 days. By contrast, PGE2 treatment effected a dose-dependent decrease in α-SMA and collagen I expression that was observed 2 days after PGE2 addition, peaked at 3 days, and persisted through 8 days in culture. This effect was not explained by an increase in myofibroblast apoptosis, and indeed, reintroduction of TGF-β1 2 days after addition of PGE2 prompted dedifferentiated fibroblasts to re-express α-SMA, indicating redifferentiation to myofibroblasts. This effect of PGE2 was associated with inhibition of focal adhesion kinase signaling, and a focal adhesion kinase inhibitor was also capable of reversing myofibroblast phenotype. These data unambiguously demonstrate reversal of established myofibroblast differentiation. Because many patients have established or even advanced fibrosis by the time they seek medical attention, this capacity of PGE2 has the potential to be harnessed for therapy of late-stage fibrotic disorders.

7 May 2018 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
LPLoka Raghu Kumar Penke
Loka Raghu Kumar Penke
JSJennifer Speth
Jennifer Speth
VDVijaya L. Dommeti
Vijaya L. Dommeti
EWEric S. White
Eric S. White
IBIngrid L. Bergin
Ingrid L. Bergin
MPMarc Peters-Golden
Marc Peters-Golden
While the transcription factor forkhead box M1 (FOXM1) is well known as a proto-oncogene, its potential role in lung fibroblast activation has never been explored. Here, we show that FOXM1 is more highly expressed in fibrotic than in normal lung fibroblasts in humans and mice. FOXM1 was required not only for cell proliferation in response to mitogens, but also for myofibroblast differentiation and apoptosis resistance elicited by TGF-β. The lipid mediator PGE2, acting via cAMP signaling, was identified as an endogenous negative regulator of FOXM1. Finally, genetic deletion of FOXM1 in fibroblasts or administration of the FOXM1 inhibitor Siomycin A in a therapeutic protocol attenuated bleomycin-induced pulmonary fibrosis. Our results identify FOXM1 as a driver of lung fibroblast activation and underscore the therapeutic potential of targeting FOXM1 for pulmonary fibrosis.

22 March 2021 in JCI Insight
Verified
Journal Article
Open access
PDF file
SFSean M. Fortier
Sean M. Fortier
LPLoka Raghu Kumar Penke
Loka Raghu Kumar Penke
DKDana King
Dana King
TPTho X. Pham
Tho X. Pham
GLGiovanni Ligresti
Giovanni Ligresti
MPMarc Peters-Golden
Marc Peters-Golden
Myofibroblasts are the major cellular source of collagen, and their accumulation — via differentiation from fibroblasts and resistance to apoptosis — is a hallmark of tissue fibrosis. Clearance of myofibroblasts by dedifferentiation and restoration of apoptosis sensitivity has the potential to reverse fibrosis. Prostaglandin E 2 (PGE 2 ) and mitogens such as FGF2 have each been shown to dedifferentiate myofibroblasts, but — to our knowledge — the resultant cellular phenotypes have neither been comprehensively characterized or compared. Here, we show that PGE 2 elicited dedifferentiation of human lung myofibroblasts via cAMP/PKA, while FGF2 utilized MEK/ERK. The 2 mediators yielded transitional cells with distinct transcriptomes, with FGF2 promoting but PGE 2 inhibiting proliferation and survival. The gene expression pattern in fibroblasts isolated from the lungs of mice undergoing resolution of experimental fibrosis resembled that of myofibroblasts treated with PGE 2 in vitro. We conclude that myofibroblast dedifferentiation can proceed via distinct programs exemplified by treatment with PGE 2 and FGF2, with dedifferentiation occurring in vivo most closely resembling the former.

1 June 2014 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
LPLoka Raghu Kumar Penke
Loka Raghu Kumar Penke
SHSteven K. Huang
Steven K. Huang
EWEric S. White
Eric S. White
MPMarc Peters-Golden
Marc Peters-Golden
Differentiation of lung fibroblasts into contractile protein-expressing myofibroblasts by transforming growth factor-β1 (TGF-β1) is a critical event in the pathogenesis of pulmonary fibrosis. Transcription of the contractile protein α-smooth muscle actin (α-SMA) is mediated by the transcription factor serum-response factor (SRF) along with its co-activator, myocardin-related transcription factor-A (MRTF-A). The endogenous lipid mediator prostaglandin E2 (PGE2) exerts anti-fibrotic effects, including the inhibition of myofibroblast differentiation. However, the mechanism by which PGE2 inhibits α-SMA expression is incompletely understood. Here, we show in normal lung fibroblasts that PGE2 reduced the nuclear accumulation of MRTF-A·SRF complexes and consequently inhibited α-SMA promoter activation. It did so both by independently inhibiting SRF gene expression and nuclear import of MRTF-A. We identified that p38 MAPK is critical for TGF-β1-induced SRF gene expression and that PGE2 inhibition of SRF expression is associated with its ability to inhibit p38 activation. Its inhibition of MRTF-A import occurs via activation of cofilin 1 and inactivation of vasodilator-stimulated phosphoprotein. Similar effects of PGE2 on SRF gene expression were observed in fibroblasts from the lungs of patients with idiopathic pulmonary fibrosis. Thus, PGE2 is the first substance described to prevent myofibroblast differentiation by disrupting, via distinct mechanisms, the actions of both SRF and MRTF-A.

1 December 2017 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
DSDaniel J. Schneider
Daniel J. Schneider
JSJennifer Speth
Jennifer Speth
LPLoka Raghu Kumar Penke
Loka Raghu Kumar Penke
SWScott H. Wettlaufer
Scott H. Wettlaufer
JSJoel A. Swanson
Joel A. Swanson
MPMarc Peters-Golden
Marc Peters-Golden
Extracellular vesicles, including exosomes and shed microvesicles (MVs), can be internalized by recipient cells to modulate function. Although the mechanism by which extracellular vesicles are internalized is incompletely characterized, it is generally considered to involve endocytosis and an initial surface-binding event. Furthermore, modulation of uptake by microenvironmental factors is largely unstudied. Here, we used flow cytometry, confocal microscopy, and pharmacologic and molecular targeting to address these gaps in knowledge in a model of pulmonary alveolar cell-cell communication. Alveolar macrophage–derived MVs were fully internalized by alveolar epithelial cells in a time-, dose-, and temperature-dependent manner. Uptake was dependent on dynamin and actin polymerization. However, it was neither saturable nor dependent on clathrin or receptor binding. Internalization was enhanced by extracellular proteins but was inhibited by cigarette smoke extract via oxidative disruption of actin polymerization. We conclude that MV internalization occurs via a pathway more consistent with fluid-phase than receptor-dependent endocytosis and is subject to bidirectional modulation by relevant pathologic perturbations.